Meeting
2023 ASCO Quality Care Symposium
Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar.
Authors
Yimeng Li
Yale School of Public Health, New Haven, CT
Yimeng Li, Szu-Chun Yang, Anne C. Chiang, Cary Philip Gross, Shi-Yi Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Real-World Evidence
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 539)
DOI
10.1200/OP.2023.19.11_suppl.539
Abstract #
539
Poster Bd #
L14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.
First Author: Itamar Sela
Poster
2021 ASCO Annual Meeting
EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.
First Author: Christos Chouaid
Poster
2016 ASCO Annual Meeting
Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
First Author: Shun Lu
Poster
2013 ASCO Annual Meeting
65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
First Author: Wolfgang Schuette